Objective: To update and expand The North American Menopause Society’s evidence-based position on nonhormonal management of menopause-associated vasomotor symptoms (VMS), previously a portion of ...

Elinzanetant reduced vasomotor symptoms frequency and severity in women with or at high risk of HR-positive breast cancer in ...

Use of menopausal hormone therapy among midlife active-duty servicewomen in the U.S. is twice as high as the general ...

My primary care physician has been using an AI-assisted device during our office visits that transcribes and records our ...

The exact interplay of estrogen and hot flashes isn't entirely understood, but they may be an indicator of your body trying ...

Elinzanetant significantly reduced moderate to severe vasomotor symptoms in women on adjuvant endocrine therapy for hormone receptor–positive breast cancer. The OASIS 4 study demonstrated ...

Vasomotor Symptoms (VMS): Symptoms associated with menopause, including hot flashes and night sweats, caused by changes in hormone levels. Hormone Therapy (HT): A treatment that involves the ...

My primary care physician has been using an AI-assisted device during our office visits that transcribes and records our ...

OASIS 3 investigated the efficacy and safety of elinzanetant for the treatment of vasomotor symptoms associated with menopause over 52 weeks and randomized 628 postmenopausal women between 40 and ...

Vasomotor symptoms may be caused by thermoregulatory ... Dosing and need for ongoing therapy for relief of menopause symptoms should be assessed periodically. Micronized progesterone 300 mg ...